account_circleRecruiting

Advanced non-small cell lung cancer, Cancer

Expanded access to provide BAY2927088 for the treatment of locally advanced or metastatic NSCLC with HER2 mutation

Trial purpose

The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.

Key Participants Requirements

Sex

All

Age

18 Years

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
BAY2927088
Accepts Healthy Volunteer
N/A

Trial design

Single Patient Expanded Access Use of BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC with HER2 mutation
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A